Medicina
Departamento
Commonwealth Scientific and Industrial Research Organisation
Canberra, AustraliaPublicacións en colaboración con investigadores/as de Commonwealth Scientific and Industrial Research Organisation (58)
2024
-
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial
Nature Medicine, Vol. 30, Núm. 1, pp. 271-278
-
Exploring management and outcomes of elderly patients with glioblastoma using data from two randomised trials (GEINO1401/EX-TEM)
Journal of Neuro-Oncology
2023
-
A meta-analysis of GFR slope as a surrogate endpoint for kidney failure
Nature Medicine, Vol. 29, Núm. 7, pp. 1867-1876
-
Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results from a Randomized, Open-Label, Phase III Trial
Journal of Clinical Oncology, Vol. 41, Núm. 11, pp. 2007-2019
-
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial
The Lancet, Vol. 402, Núm. 10417, pp. 2077-2090
-
Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: Systematic literature review of real-world evidence
Multiple Sclerosis and Related Disorders, Vol. 69
-
Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study
British Journal of Cancer, Vol. 128, Núm. 1, pp. 137-147
-
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial
The Lancet, Vol. 401, Núm. 10388, pp. 1584-1594
2022
-
Acute Treatment Effects on GFR in Randomized Clinical Trials of Kidney Disease Progression
Journal of the American Society of Nephrology : JASN, Vol. 33, Núm. 2, pp. 291-303
-
Erratum: Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk (European journal of human genetics : EJHG (2022) 30 3 (349-362))
European journal of human genetics : EJHG
-
Polygenic risk modeling for prediction of epithelial ovarian cancer risk
European journal of human genetics : EJHG, Vol. 30, Núm. 3, pp. 349-362
-
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
New England Journal of Medicine, Vol. 386, Núm. 7, pp. 629-639
2021
-
Diabetes-Related Factors and the Effects of Ticagrelor Plus Aspirin in the THEMIS and THEMIS-PCI Trials
Journal of the American College of Cardiology, Vol. 77, Núm. 19, pp. 2366-2377
-
Effect of SGLT2 inhibitors on stroke and atrial fibrillation in diabetic kidney disease: Results from the CREDENCE trial and meta-analysis
Stroke, Vol. 52, Núm. 5, pp. 1545-1556
-
Global Chronic Total Occlusion Crossing Algorithm: JACC State-of-the-Art Review
Journal of the American College of Cardiology, Vol. 78, Núm. 8, pp. 840-853
-
Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies candidate susceptibility genes for breast and ovarian cancer
Human Genetics and Genomics Advances, Vol. 2, Núm. 3
-
Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA)
Journal of Clinical Oncology, Vol. 39, Núm. 10, pp. 1108-1118
2020
-
Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium
British Journal of Cancer, Vol. 123, Núm. 5, pp. 793-802
-
Fibromyalgia assessment screening tool: Clues to fibromyalgia on a multidimensional health assessment questionnaire for routine care
Journal of Rheumatology, Vol. 47, Núm. 5, pp. 761-769
-
Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes
Nature Genetics, Vol. 52, Núm. 1, pp. 56-73